June 2, 2021 04:39 PM EDTUpdated June 3, 07:27 AM

#ASCO21: Novartis keeps building out survival data for Kisqali, hoping to add pressure on Pfizer's Ibrance

Max Gelman

Senior Editor

As Novartis’ Kisqali for breast cancer trails Pfizer’s Ibrance in sales, the Swiss biopharma continues to trot out long-term survival data it hopes will flesh …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASCO21: Novartis keeps building out survival data for Kisqali, hoping to add pressure on Pfizer's Ibrance

Max Gelman

Senior Editor

Sign up to read this article for free.

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

#AS­CO21: No­var­tis keeps build­ing out sur­vival da­ta for Kisqali, hop­ing to add pres­sure on Pfiz­er's Ibrance

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

#ASCO21: Novartis keeps building out survival data for Kisqali, hoping to add pressure on Pfizer's Ibrance

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market